New Urine-based Test improves Prostate Cancer Detection

New Urine-based Test improves Prostate Cancer Detection

The University of Michigan Comprehensive Cancer Center has developed a new test that has improved prostate cancer detection. The urine-based test known as Mi-Prostate Score, or MiPS, was able to detect more aggressive forms of prostate cancer.

In fact, it was found to be better than available models of testing that are based on prostate serum antigen or PSA levels. The new test combines PSA with two markers for prostate cancer, T2:ERG and PCA3. Both these markers can be detected through urine sample.

Study's lead author Scott A. Tomlins from the university said, "Around 50 percent of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions".

For the study, the researchers have studied 1,977 men who have undergone prostate biopsy owing to increased PSA levels. Using urine samples, the researchers carried out MiPS testing and compared the results with different combinations of PSA, PCA3, T2:ERG and other PSA-based risk calculators.

Main aim of the researchers was to know the efficacy level of individual biomarkers and combination of biomarkers in detecting the probability of cancer and likelihood of cancer. The researchers affirmed that if MiPS cutoff score is used to decide whether or not patients should undergo biopsy. Effective testing reduces the biopsies by one-third.

Tomlins affirmed that MiPS provides better assessment for prostate cancer. The US Food and Drug Administration has approved PCA3 for the prostate cancer risk assessment in men having an earlier negative biopsy.

The researchers affirmed that the test is part of a wider effort at the university to come up with better ways to diagnose prostate cancer.

Popular Stories